Use of cholesterol-lowering medications in the United States from 1991 to 1997

American Journal of Medicine

Volumn 108, Issue 6, 2000, Pages 496-499

  Siegel, David ^a,b   Lopez, Julio ^c,d   Meier, Joy ^c,d  

^a Medical Service   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PROBUCOL; SIMVASTATIN; TRIACYLGLYCEROL;

ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG USE; HUMAN; HYPERCHOLESTEROLEMIA; INFORMATION; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES;

ANTICHOLESTEREMIC AGENTS; DRUG COSTS; DRUG UTILIZATION; HUMANS; PATIENT SELECTION; PHARMACIES; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PRESCRIPTIONS, DRUG; UNITED STATES;

EID: 0034655284     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(00)00319-3     Document Type: Article

References (29)

1. Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in coronary drug project patients long-term benefit with niacin . JACC. 8:1986;1245-1255.
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian simvastatin survival study (4S) . Lancet. 344:1994;1383-1389.
3. Byington R.P., Jukema J.W., Jukka T.S., et al. Reduction in cardiovascular events during pravastatin therapy. Circulation. 92:1995;2419-2425.
4. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. NEJM. 335:1996;1001-1009.
5. Shepherd J., Cobbe S.T., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. NEJM. 333:1995;1301-1307.
6. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 148:1988;36-69.
7. Nieto F.J., Alonso J., Chambless L.E., et al. Populations awareness and control of hypertension and hypercholesterolemia. Arch Intern Med. 155:1995;677-684.
8. Pieper R.M., Arnett D.K., McGovern P.G., et al. Trends in cholesterol knowledge and screening and hypercholesterolemia awareness and treatment, 1980-1992. Arch Intern Med. 157:1997;2326-2332.
9. Stafford R.S., Blumenthal D., Pasternak R.C. Variations in cholesterol management practices of U. S. physicians. JACC. 29:1997;139-146.
10. Lemaitre R.N., Furberg C.D., Newman A.B., et al. Time trends in the use of cholesterol-lowering agents in older adults. Arch Intern Med. 158:1998;1761-1768.
11. McBride P., Schrott H.G., Plane M.B., et al. Primary care practice adherence to national cholesterol education program guidelines for patients with coronary heart disease. Arch Intern Med. 158:1998;1238-1244.
12. Andrade S.E., Walker A.M., Gottlieb L.K., et al. Discontinuation of antihyperlipidemic drugs. Do rates reported in clinical trials reflect rates in primary care settings? NEJM. 332:1995;1125-1131.
13. Avorn J., Monette J., Lacour A., et al. Persistence of use of lipid-lowering medications. JAMA. 279:1998;1458-1462.
14. Marcelino J.J., Feingold K.R. Inadequate treatment with HMG-Co A reductase inhibitors by health care providers. Am J Med. 100:1996;605-610.
15. Am Drug. 215:1998;46-53.
16. Siegel D., Lopez J. Trends in antihypertensive drug use in the United States. JAMA. 278:1997;1745-1748.
17. 1997 Drug Topics Redbook. 1997;Medical Economics, Montvale, NJ.
18. Hough J. IMS hospital pharmacy review leading dollar volume pharmaceuticals . Hosp Pharm. 1997:1998;33:498-33:522.
19. Heart and Stroke Facts, 1994 Statistical Supplement. 1994;Am Heart Assocation, Dallas.
20. Gartside P.S., Glueck C.J. Relationship of dietary intake to hospital admission for coronary heart and vascular disease the NHANES II national probability study . J Am Col Nutr. 12:1993;676-684.
21. Gartside P.S., Glueck C.J. The important role of modifiable dietary and behavioral characteristics in the causation and prevention of coronary heart disease hospitalizations and mortality the prospective NHANES I follow-up study . J Am Col Nutr. 14:1995;71-79.
22. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA. 269:1993;3015-3023.
23. Davidson M.H., Stein E.A., Dujovne C.A., et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol. 79:1997;38-42.
24. Jones P., Kafonek S., Hunninghake D. Comparison dose efficacy study of atorvastatin, versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 81:1998;582-587.
25. 1998 Industry Profile and Healthcare Factbook. Reston, Vir: National Wholesale Druggists' Association; 1998:109.
26. Garber A.M., Browner W.S., Hulley S.B. Cholesterol screening in asymptomatic adults, revisited. Ann Intern Med. 124:1996;518-531.
27. LaRosa J.C. Cholesterol agonistics. Ann Intern Med. 124:1996;505-508.
28. Forrester J.S., Sha P.K. Using serum cholesterol as a screening test for preventing coronary heart disease the five fundamental flaws of the American College of Physicians guidelines . Am J Cardiol. 79:1997;790-792.
29. Grundy S.M., Balady G.J., Criqui M.H., et al. When to start cholesterol-lowering therapy in patients with coronary heart disease a statement for healthcare professionals from the American Heart Association task force on risk reduction . Circulation. 95:1997;1683-1685.